EUVIMEDEUVIMED entdecken
Crossref

Chondrocyte‐Targeted Delivery System of Sortase A‐Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy

Wenjing Yan, Ying Li, Shuqian Xie, W Andy Tao, Jing Hu, Haohan Liu, Guiyuan Zhang, Fengying Liu, Yamei Nie, Xue Chen, Xing Zhang, Yufeng Liu und 5 weitere

Advanced Healthcare Materials · 2024-06 · 13 (16)

DOI: 10.1002/adhm.202303510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 08.04.2024. Verfasst von Wenjing Yan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, 210003,…. Hauptthemen laut MEDLINE: Bacterial Proteins, Chondrocytes, Cysteine Endopeptidases, Extracellular Vesicles. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Opening Foundation of Jiangsu Provincial Health Development Research Center, JSHD2022056.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drug delivery and the reduction of off‐target effects are crucial for the promising clinical application of nucleic acid drugs. To address this challenge, a new approach for treating osteoarthritis (OA) that accurately delivers antisense oligonucleotides (ASO) targeting matrix metalloproteinase‐13 (ASO‐MMP13) to chondrocytes, is developed. Small extracellular vesicles (exos) are ligated with chondrocyte affinity peptide (CAP) using Sortase A and subsequently incubated with cholesterol‐modified ASO‐MMP13 to construct a chondrocyte‐targeted drug delivery exo (CAP‐exoASO). Compared with exos without CAP (ExoASO), CAP‐exoASOs attenuate IL‐1β‐induced chondrocyte damage and prolong the retention time of ASO‐MMP13 in the joint without distribution in major organs following intra‐articular injection. Notably, CAP‐exoASOs decrease MMP13 expression ( P < 0.001) and upregulate COL2A1 expression ( P = 0.006), resulting in reorganization of the cartilage matrix and alleviation of progression in the OA model. Furthermore, the Osteoarthritis Research Society International (OARSI) score of articular cartilage tissues treated with CAP‐exoASO is comparable with that of healthy rats ( P = 0.148). A mechanistic study demonstrates that CAP‐exoASO may reduce inflammation by suppressing the IL‐17 and TNF signaling pathways. Based on the targeted delivery effect, CAP‐exoASOs successfully accomplish cartilage repair and have considerable potential for development as a promising therapeutic modality for satisfactory OA therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacterial ProteinsChondrocytesCysteine EndopeptidasesExtracellular VesiclesMatrix Metalloproteinase 13OsteoarthritisAnimalsMaleRatsAminoacyltransferasesCartilage, ArticularDrug Delivery SystemsOligonucleotides, AntisenseRats, Sprague-Dawley

Stichwörter der Autor:innen

MMP13Sortase Aantisense oligonucleotidesosteoarthritissmall extracellular vesiclestargeted delivery

Substanzen

AminoacyltransferasesBacterial ProteinsCysteine EndopeptidasesMatrix Metalloproteinase 13Oligonucleotides, Antisensesortase A

Autor:innen und Institutionen

  • Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, 210003, China.
  • Center of Clinical Laboratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, China.
  • Department of Epidemiology, School of Public Health of Suzhou University, Suzhou, Jiangsu, 215127, China.
  • Departments of Chemistry and Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
  • State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing, Jiangsu, 210096, China.
  • Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.

ORCID-Profile: Hongtao Xu, Shizhi Wang

Förderung

  • Fundamental Research Funds for the Central Universities
  • Opening Foundation of Jiangsu Provincial Health Development Research Center
  • JSHD2022056
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Outstanding Postdoc Research Foundation of Jiangsu Province
  • Natural Science Foundation of Jiangsu Province
  • China Postdoctoral Science Foundation
  • Nanjing Science and Technology Innovation Project for Overseas Students

Zitieren

APA

Yan, W., Li, Y., Xie, S., Tao, W. A., Hu, J., Liu, H., Zhang, G., Liu, F., Nie, Y., Chen, X., Zhang, X., Liu, Y., Wei, D., Ma, C., Zhang, H., Xu, H., & Wang, S. (2024). Chondrocyte‐Targeted Delivery System of Sortase A‐Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy. Advanced Healthcare Materials, 13(16). https://doi.org/10.1002/adhm.202303510

Vancouver

Yan W, Li Y, Xie S, Tao WA, Hu J, Liu H, et al. Chondrocyte‐Targeted Delivery System of Sortase A‐Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy. Advanced Healthcare Materials. 2024;13(16). doi:10.1002/adhm.202303510

BibTeX
@article{Yan2024,
  author = {Yan, Wenjing and Li, Ying and Xie, Shuqian and Tao, W Andy and Hu, Jing and Liu, Haohan and Zhang, Guiyuan and Liu, Fengying and Nie, Yamei and Chen, Xue and Zhang, Xing and Liu, Yufeng and Wei, Dong and Ma, Changyan and Zhang, Hao and Xu, Hongtao and Wang, Shizhi},
  title = {Chondrocyte‐Targeted Delivery System of Sortase A‐Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {16},
  doi = {10.1002/adhm.202303510}
}
Kostenlos starten →